CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ZNF638 (ImmuneEditome ID:27332)

1. Gene summary of enriched editing regions for ZNF638

check button Gene summary
Gene informationGene symbol

ZNF638

Gene ID

27332

GeneSynonymsNP220|ZFML|Zfp638
GeneCytomap

2p13.2

GeneTypeprotein-coding
GeneDescriptionzinc finger protein 638|CTCL tumor antigen se33-1|CTCL-associated antigen se33-1|NP220 nuclear protein|cutaneous T-cell lymphoma-associated antigen se33-1|nuclear protein 220|zinc finger matrin-like protein
GeneModificationdate20230329
UniprotIDQ14966;C9JMR2;C9JSD0;A0A096LNQ0;C9JHV0;A0A096LNR2;A0A096LPB4;C9JWN0;A0A096LPI0;A0A096LNX0
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr2:71335194-71336339:+ENST00000487707.1ENSG00000075292.17ZNF638ncRNA_intronicL1MC5,AluJo,AluSpchr2:71335194-71336339:+.alignment
chr2:71354529-71355184:+ENST00000264447.7ENSG00000075292.17ZNF638intronicAluYc,AluSq2,(ATTTTT)nchr2:71354529-71355184:+.alignment
chr2:71354529-71355184:+ENST00000409544.4ENSG00000075292.17ZNF638intronicAluYc,AluSq2,(ATTTTT)nchr2:71354529-71355184:+.alignment
chr2:71354529-71355184:+ENST00000410075.4ENSG00000075292.17ZNF638intronicAluYc,AluSq2,(ATTTTT)nchr2:71354529-71355184:+.alignment
chr2:71354529-71355184:+ENST00000464375.4ENSG00000075292.17ZNF638intronicAluYc,AluSq2,(ATTTTT)nchr2:71354529-71355184:+.alignment
chr2:71354529-71355184:+ENST00000466330.4ENSG00000075292.17ZNF638intronicAluYc,AluSq2,(ATTTTT)nchr2:71354529-71355184:+.alignment
chr2:71354529-71355184:+ENST00000466975.4ENSG00000075292.17ZNF638intronicAluYc,AluSq2,(ATTTTT)nchr2:71354529-71355184:+.alignment
chr2:71354529-71355184:+ENST00000475743.1ENSG00000075292.17ZNF638intronicAluYc,AluSq2,(ATTTTT)nchr2:71354529-71355184:+.alignment
chr2:71354529-71355184:+ENST00000494621.4ENSG00000075292.17ZNF638intronicAluYc,AluSq2,(ATTTTT)nchr2:71354529-71355184:+.alignment
chr2:71386873-71387626:+ENST00000491843.2ENSG00000075292.17ZNF638ncRNA_intronicL1M5,AluSz,AluSxchr2:71386873-71387626:+.alignment
chr2:71432191-71433051:+ENST00000409407.3ENSG00000075292.17ZNF638ncRNA_intronicAluSx,AluJbchr2:71432191-71433051:+.alignment
chr2:71432191-71433051:+ENST00000460310.1ENSG00000075292.17ZNF638ncRNA_intronicAluSx,AluJbchr2:71432191-71433051:+.alignment
chr2:71432191-71433051:+ENST00000472758.4ENSG00000075292.17ZNF638ncRNA_intronicAluSx,AluJbchr2:71432191-71433051:+.alignment
chr2:71432191-71433051:+ENST00000483421.6ENSG00000075292.17ZNF638ncRNA_intronicAluSx,AluJbchr2:71432191-71433051:+.alignment
chr2:71432191-71433051:+ENST00000487638.4ENSG00000075292.17ZNF638ncRNA_intronicAluSx,AluJbchr2:71432191-71433051:+.alignment
chr2:71432191-71433051:+ENST00000488126.2ENSG00000075292.17ZNF638ncRNA_intronicAluSx,AluJbchr2:71432191-71433051:+.alignment


Top

2. Tumor-specific enriched editing regions for ZNF638


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000075292.17,ZNF638COADPathEAG3.1667e-023.0104e-030.5078image
ENSG00000075292.17,ZNF638TGCTCliEAG5.2113e-031.1674e-020.3318image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for ZNF638


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for ZNF638


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000075292.17,ZNF638
ESCAEAGIRENSG00000108846.11chr1750663680:50664111:50665152:50665245-0.36923.9062e-023.2503e-06-0.4202imageNACIN1;ADAR;AUH;BCCIP;BUD13;CSTF2T;DDX54;DGCR8;DKC1;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FKBP4;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;LARP7;LIN28A;LIN28B;MBNL2;MSI1;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM5;RBM6;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;WTAP;YTHDC1;YTHDF1NAT_cells_CD4_memory_restingGSVA_HALLMARK_GLYCOLYSIS
ENSG00000075292.17,ZNF638
ESCAEAGIRENSG00000119431.5chr9113375452:113375526:113376728:113376925-0.37743.6589e-021.0956e-06-0.4246imageNAUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;LARP4B;LIN28;LSM11;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;U2AF1;U2AF2;XRN2;YTHDC1;YTHDF1;ZNF184NAMacrophages_M0GSVA_HALLMARK_HYPOXIA
ENSG00000075292.17,ZNF638
ESCAEAGIRENSG00000127526.9chr1916551758:16551868:16551992:165523280.46622.1195e-031.0606e-060.4235imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YTHDF2;YWHAG;ZC3H7B;ZNF184NAT_cells_CD8GSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000075292.17,ZNF638
ESCAEAGMEXENSG00000122406.8chr192836189:92836392:92837455:92837537:92840550:92840639:92841765:928418620.43905.8930e-034.5697e-070.4362imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RBM6;RC3H1;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;WTAP;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAT_cells_gamma_deltaGSVA_HALLMARK_MITOTIC_SPINDLE

More results



Top

5. Enriched editing regions and immune infiltration for ZNF638


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000075292.17,ZNF638BLCAEAGPlasma_cells3.6500e-030.3638image
chr2:71386873-71387626:+BRCAEERMacrophages_M19.8980e-030.2942image
chr2:71432191-71433051:+BRCAEERNK_cells_activated4.9656e-020.2590image
ENSG00000075292.17,ZNF638BRCAEAGT_cells_CD82.3027e-030.2815image
chr2:71432191-71433051:+CESCEERT_cells_regulatory_(Tregs)8.9058e-030.5685image
ENSG00000075292.17,ZNF638CESCEAGDendritic_cells_activated1.1673e-02-0.4697image
ENSG00000075292.17,ZNF638COADEAGNK_cells_resting9.5899e-03-0.4809image
chr2:71432191-71433051:+ESCAEERT_cells_regulatory_(Tregs)3.4782e-02-0.2458image
chr2:71432191-71433051:+KIRCEERT_cells_CD88.9730e-030.3659image
ENSG00000075292.17,ZNF638KIRCEAGT_cells_CD81.7530e-020.2894image
chr2:71432191-71433051:+KIRPEERDendritic_cells_activated1.5917e-020.5190image
ENSG00000075292.17,ZNF638KIRPEAGDendritic_cells_activated1.6202e-020.5178image
ENSG00000075292.17,ZNF638LAMLEAGMonocytes1.3759e-020.2190image
chr2:71386873-71387626:+LUADEERT_cells_CD4_memory_resting5.4581e-03-0.3991image
chr2:71432191-71433051:+LUADEERPlasma_cells7.2915e-030.3403image
ENSG00000075292.17,ZNF638LUADEAGT_cells_CD4_memory_resting7.8181e-04-0.3290image
ENSG00000075292.17,ZNF638LUSCEAGMacrophages_M02.9561e-02-0.2498image
chr2:71386873-71387626:+OVEERNeutrophils1.1263e-030.4041image
ENSG00000075292.17,ZNF638OVEAGNeutrophils1.1496e-030.3145image
ENSG00000075292.17,ZNF638PAADEAGT_cells_regulatory_(Tregs)3.2039e-02-0.4688image
chr2:71386873-71387626:+PRADEERMast_cells_resting1.6433e-020.3973image
chr2:71354529-71355184:+STADEERMast_cells_activated1.4876e-030.3048image
chr2:71386873-71387626:+STADEERNK_cells_resting1.2435e-020.2345image
chr2:71432191-71433051:+STADEERT_cells_follicular_helper2.4036e-020.2715image
ENSG00000075292.17,ZNF638STADEAGNK_cells_resting3.8013e-040.2572image
chr2:71386873-71387626:+TGCTEERB_cells_naive9.8726e-03-0.2649image
chr2:71432191-71433051:+TGCTEERMacrophages_M23.6692e-02-0.3196image
ENSG00000075292.17,ZNF638TGCTEAGB_cells_naive5.6555e-03-0.2695image
ENSG00000075292.17,ZNF638THCAEAGT_cells_regulatory_(Tregs)2.5421e-020.3946image


Top

6. Enriched editing regions and immune gene sets for ZNF638


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000075292.17,ZNF638BLCAGSVA_HALLMARK_MYC_TARGETS_V1EAG1.0208e-030.4072image
chr2:71386873-71387626:+BLCAGSVA_HALLMARK_PANCREAS_BETA_CELLSEER4.8142e-020.3364image
ENSG00000075292.17,ZNF638BRCAGSVA_HALLMARK_HEME_METABOLISMEAG4.8352e-060.4118image
chr2:71386873-71387626:+BRCAGSVA_HALLMARK_BILE_ACID_METABOLISMEER3.3292e-030.3326image
ENSG00000075292.17,ZNF638CESCGSVA_HALLMARK_MTORC1_SIGNALINGEAG6.4760e-030.5021image
chr2:71432191-71433051:+CESCGSVA_HALLMARK_IL2_STAT5_SIGNALINGEER2.0760e-020.5128image
ENSG00000075292.17,ZNF638COADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG2.5608e-020.4212image
ENSG00000075292.17,ZNF638ESCAGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.1448e-040.3196image
chr2:71386873-71387626:+ESCAGSVA_HALLMARK_APICAL_SURFACEEER7.6715e-030.2857image
chr2:71432191-71433051:+ESCAGSVA_HALLMARK_HYPOXIAEER3.6364e-020.2438image
chr2:71386873-71387626:+KIRCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER2.4789e-020.3902image
ENSG00000075292.17,ZNF638KIRCGSVA_HALLMARK_MTORC1_SIGNALINGEAG2.8292e-040.4299image
chr2:71432191-71433051:+KIRCGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER2.7022e-030.4154image
ENSG00000075292.17,ZNF638LAMLGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG2.8771e-040.3178image
ENSG00000075292.17,ZNF638LUADGSVA_HALLMARK_ANDROGEN_RESPONSEEAG5.7828e-050.3891image
chr2:71386873-71387626:+LUADGSVA_HALLMARK_APICAL_SURFACEEER2.2269e-030.4353image
chr2:71432191-71433051:+LUADGSVA_HALLMARK_ANDROGEN_RESPONSEEER2.4946e-020.2870image
ENSG00000075292.17,ZNF638LUSCGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG1.3733e-02-0.2816image
chr2:71386873-71387626:+OVGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.5699e-020.3056image
ENSG00000075292.17,ZNF638OVGSVA_HALLMARK_IL2_STAT5_SIGNALINGEAG2.2770e-040.3540image
chr2:71432191-71433051:+OVGSVA_HALLMARK_APOPTOSISEER1.9751e-030.4118image
ENSG00000075292.17,ZNF638PAADGSVA_HALLMARK_ANDROGEN_RESPONSEEAG6.9464e-030.5703image
chr2:71386873-71387626:+PRADGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER5.0909e-030.4569image
ENSG00000075292.17,ZNF638PRADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG2.5161e-020.3018image
chr2:71354529-71355184:+STADGSVA_HALLMARK_APOPTOSISEER3.5426e-040.3406image
ENSG00000075292.17,ZNF638STADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG3.2645e-070.3631image
chr2:71386873-71387626:+STADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER3.8861e-040.3281image
chr2:71432191-71433051:+TGCTGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER4.5898e-040.5113image
ENSG00000075292.17,ZNF638TGCTGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG1.7603e-050.4075image
chr2:71386873-71387626:+TGCTGSVA_HALLMARK_COAGULATIONEER1.3262e-030.3264image
ENSG00000075292.17,ZNF638THCAGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG4.5222e-020.3565image
ENSG00000075292.17,ZNF638THYMGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.0462e-040.7456image


Top

7. Enriched editing regions and drugs for ZNF638


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000075292.17,ZNF638BLCABI.D1870EAG2.9706e-05-0.5040image
chr2:71386873-71387626:+BLCABIRB.0796EER3.6576e-03-0.4783image
ENSG00000075292.17,ZNF638BRCAABT.263EAG1.3600e-040.3513image
chr2:71386873-71387626:+BRCAABT.263EER2.8582e-040.4100image
chr2:71432191-71433051:+BRCAJNJ.26854165EER2.2664e-02-0.2989image
ENSG00000075292.17,ZNF638CESCJNK.Inhibitor.VIIIEAG4.2146e-03-0.5239image
chr2:71432191-71433051:+CESCDasatinibEER6.3039e-03-0.5888image
ENSG00000075292.17,ZNF638COADCisplatinEAG2.1964e-020.4312image
ENSG00000075292.17,ZNF638ESCAImatinibEAG6.4021e-04-0.3036image
chr2:71386873-71387626:+ESCAFTI.277EER7.3222e-03-0.2873image
chr2:71432191-71433051:+ESCABI.D1870EER4.5694e-03-0.3262image
chr2:71386873-71387626:+KIRCEHT.1864EER1.9798e-02-0.4038image
ENSG00000075292.17,ZNF638KIRCAG.014699EAG2.1873e-040.4369image
chr2:71432191-71433051:+KIRCAG.014699EER3.3231e-030.4074image
ENSG00000075292.17,ZNF638LAMLGefitinibEAG2.8968e-030.2633image
ENSG00000075292.17,ZNF638LUADElesclomolEAG8.4928e-04-0.3269image
chr2:71386873-71387626:+LUADGSK269962AEER4.0634e-05-0.5612image
ENSG00000075292.17,ZNF638LUSCLenalidomideEAG1.0220e-02-0.2930image
chr2:71386873-71387626:+OVEpothilone.BEER5.4718e-03-0.3487image
ENSG00000075292.17,ZNF638OVDMOGEAG8.7552e-03-0.2558image
chr2:71432191-71433051:+OVDocetaxelEER2.3640e-03-0.4053image
chr2:71386873-71387626:+PRADBMS.509744EER1.2830e-03-0.5158image
chr2:71386873-71387626:+SKCMBX.795EER2.8361e-02-0.4004image
ENSG00000075292.17,ZNF638SKCMAZD.2281EAG4.1006e-02-0.3423image
chr2:71354529-71355184:+STADGemcitabineEER3.1498e-02-0.2091image
ENSG00000075292.17,ZNF638STADBicalutamideEAG1.3816e-02-0.1798image
chr2:71386873-71387626:+STADBMS.509744EER3.1686e-02-0.2023image
chr2:71432191-71433051:+TGCTCGP.082996EER5.1589e-03-0.4190image
ENSG00000075292.17,ZNF638TGCTIPA.3EAG3.0897e-040.3469image
chr2:71386873-71387626:+TGCTBicalutamideEER5.9508e-05-0.4019image
ENSG00000075292.17,ZNF638THCACytarabineEAG1.8763e-030.5285image
ENSG00000075292.17,ZNF638THYMEmbelinEAG1.4878e-03-0.6481image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType